Scancell Holdings (GB:SCLP) has released an update.
Scancell Holdings has announced a strategic partnership with PharmaJet, incorporating the Stratis Needle-free Injection System for the delivery of its SCIB1/iSCIB1+ DNA cancer vaccine aimed at treating advanced melanoma. The partnership is pivotal for both the clinical and commercial development of the vaccine, which has shown promising results in ongoing trials with the potential to enhance patient experience and treatment efficacy. Clinical data for the vaccine is anticipated in late 2024 and early 2025, leading up to a Phase 2/3 trial planned for 2025.
For further insights into GB:SCLP stock, check out TipRanks’ Stock Analysis page.
